293 related articles for article (PubMed ID: 15336648)
1. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse.
Sferra TJ; Backstrom K; Wang C; Rennard R; Miller M; Hu Y
Mol Ther; 2004 Sep; 10(3):478-91. PubMed ID: 15336648
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse.
Sferra TJ; Qu G; McNeely D; Rennard R; Clark KR; Lo WD; Johnson PR
Hum Gene Ther; 2000 Mar; 11(4):507-19. PubMed ID: 10724030
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII.
Bielicki J; McIntyre C; Anson DS
Mol Genet Metab; 2010 Dec; 101(4):370-82. PubMed ID: 20864369
[TBL] [Abstract][Full Text] [Related]
4. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells.
Ross CJ; Bastedo L; Maier SA; Sands MS; Chang PL
Hum Gene Ther; 2000 Oct; 11(15):2117-27. PubMed ID: 11044913
[TBL] [Abstract][Full Text] [Related]
5. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice.
Daly TM; Okuyama T; Vogler C; Haskins ME; Muzyczka N; Sands MS
Hum Gene Ther; 1999 Jan; 10(1):85-94. PubMed ID: 10022533
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy for murine mucopolysaccharidosis type VII.
Sands MS; Vogler C; Kyle JW; Grubb JH; Levy B; Galvin N; Sly WS; Birkenmeier EH
J Clin Invest; 1994 Jun; 93(6):2324-31. PubMed ID: 8200966
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus.
Watson GL; Sayles JN; Chen C; Elliger SS; Elliger CA; Raju NR; Kurtzman GJ; Podsakoff GM
Gene Ther; 1998 Dec; 5(12):1642-9. PubMed ID: 10023443
[TBL] [Abstract][Full Text] [Related]
8. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.
Vogler C; Sands MS; Galvin N; Levy B; Thorpe C; Barker J; Sly WS
J Inherit Metab Dis; 1998 Aug; 21(5):575-86. PubMed ID: 9728337
[TBL] [Abstract][Full Text] [Related]
9. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease.
Daly TM; Vogler C; Levy B; Haskins ME; Sands MS
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2296-300. PubMed ID: 10051635
[TBL] [Abstract][Full Text] [Related]
10. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery.
Richard M; Arfi A; Seguin J; Gandolphe C; Scherman D
Gene Ther; 2009 Jun; 16(6):746-56. PubMed ID: 19357715
[TBL] [Abstract][Full Text] [Related]
11. Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing beta-glucuronidase.
Berges BK; Yellayi S; Karolewski BA; Miselis RR; Wolfe JH; Fraser NW
Mol Ther; 2006 May; 13(5):859-69. PubMed ID: 16515890
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.
Vogler C; Sands MS; Levy B; Galvin N; Birkenmeier EH; Sly WS
Pediatr Res; 1996 Jun; 39(6):1050-4. PubMed ID: 8725268
[TBL] [Abstract][Full Text] [Related]
13. Delivery of a retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice.
Gao C; Sands MS; Haskins ME; Ponder KP
Mol Ther; 2000 Sep; 2(3):233-44. PubMed ID: 10985954
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy.
Xu L; Mango RL; Sands MS; Haskins ME; Ellinwood NM; Ponder KP
Mol Ther; 2002 Dec; 6(6):745-58. PubMed ID: 12498771
[TBL] [Abstract][Full Text] [Related]
15. Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII.
Donsante A; Levy B; Vogler C; Sands MS
J Inherit Metab Dis; 2007 Apr; 30(2):227-38. PubMed ID: 17308887
[TBL] [Abstract][Full Text] [Related]
16. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts.
Moullier P; Bohl D; Heard JM; Danos O
Nat Genet; 1993 Jun; 4(2):154-9. PubMed ID: 8348154
[TBL] [Abstract][Full Text] [Related]
17. Systemic hyperosmolality improves beta-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer.
Ghodsi A; Stein C; Derksen T; Martins I; Anderson RD; Davidson BL
Exp Neurol; 1999 Nov; 160(1):109-16. PubMed ID: 10630195
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII.
Derrick-Roberts AL; Pyragius CE; Kaidonis XM; Jackson MR; Anson DS; Byers S
Hum Gene Ther; 2014 Sep; 25(9):798-810. PubMed ID: 25003807
[TBL] [Abstract][Full Text] [Related]
19. High level expression and export of beta-glucuronidase from murine mucopolysaccharidosis VII cells corrected by a double-copy retrovirus vector.
Wolfe JH; Kyle JW; Sands MS; Sly WS; Markowitz DG; Parente MK
Gene Ther; 1995 Jan; 2(1):70-8. PubMed ID: 7712336
[TBL] [Abstract][Full Text] [Related]
20. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice.
Stein CS; Ghodsi A; Derksen T; Davidson BL
J Virol; 1999 Apr; 73(4):3424-9. PubMed ID: 10074197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
